To review all the sessions designed for basic researchers, visit www.rheumatology.org/annual. We look forward to seeing you in Philadelphia.
Staff | Issue: August 2009 |
To review all the sessions designed for basic researchers, visit www.rheumatology.org/annual. We look forward to seeing you in Philadelphia.
Progress toward targeted therapy
A perspective on B cell–targeted therapies in autoimmune disease
Save the date for the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Connect with your colleagues for an unmatched educational experience featuring exceptional sessions by leading rheumatology experts. The ACR/ARHP Annual Meeting is your gateway to global rheumatology education. With more than 450 sessions—including The Great Debate—the meeting provides boundless opportunities for professional development,…
The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…